Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Research focuses on chronic myeloid leukemia with the goal of creating a new therapy for patients Study funded by Robert & Lynda Carter Altman Family Foundation Research Fund LOS ANGELES--(BUSINESS ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Mauro: I have been ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase ...

Please provide your email address to receive an email when new articles are posted on . Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016" report to their offering. This ...

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...